ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
7.94
-0.01 (-0.13%)
At close: Apr 28, 2026, 4:00 PM EDT
7.93
-0.01 (-0.13%)
After-hours: Apr 28, 2026, 7:12 PM EDT
ARS Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 84.28 | 89.15 | 0.03 | 1.32 | 5.51 | |
| Revenue Growth (YoY) | -5.46% | 297063.33% | -97.72% | -76.10% | -69.13% | |
| Cost of Revenue | 33.6 | 20.56 | 20.27 | 17.12 | 20.27 | |
| Gross Profit | 50.67 | 68.59 | -20.24 | -15.8 | -14.77 | |
| Selling, General & Admin | 230.12 | 71.68 | 47.28 | 18.66 | 4.69 | |
| Operating Expenses | 230.12 | 71.68 | 47.28 | 18.66 | 4.69 | |
| Operating Income | -179.45 | -3.08 | -67.52 | -34.46 | -19.45 | |
| Interest Expense | -2.6 | - | - | - | -0.8 | |
| Interest & Investment Income | 10.67 | 11.37 | - | - | - | |
| Other Non Operating Income (Expenses) | - | - | 6.01 | 1.12 | 0.01 | |
| EBT Excluding Unusual Items | -171.38 | 8.29 | -61.51 | -33.34 | -20.24 | |
| Gain (Loss) on Sale of Investments | - | - | 6.85 | -0.29 | - | |
| Gain (Loss) on Sale of Assets | - | - | 0.3 | - | - | |
| Pretax Income | -171.38 | 8.29 | -54.37 | -34.68 | -20.24 | |
| Income Tax Expense | -0.08 | 0.29 | - | - | - | |
| Net Income | -171.3 | 8 | -54.37 | -34.68 | -20.24 | |
| Net Income to Common | -171.3 | 8 | -54.37 | -34.68 | -20.24 | |
| Shares Outstanding (Basic) | 99 | 97 | 95 | 40 | 29 | |
| Shares Outstanding (Diluted) | 99 | 102 | 95 | 40 | 29 | |
| Shares Change (YoY) | -3.74% | 7.54% | 138.30% | 38.39% | 42.81% | |
| EPS (Basic) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | |
| EPS (Diluted) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | |
| Free Cash Flow | -171.21 | 12.99 | -59.44 | -40.28 | -17.62 | |
| Free Cash Flow Per Share | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 | |
| Gross Margin | 60.13% | 76.94% | - | - | -268.20% | |
| Operating Margin | -212.92% | -3.46% | -225066.67% | -2618.54% | -353.32% | |
| Profit Margin | -203.25% | 8.97% | -181216.67% | -2635.41% | -367.65% | |
| Free Cash Flow Margin | -203.14% | 14.57% | -198136.67% | -3060.56% | -319.94% | |
| EBITDA | -178.08 | -3 | -67.45 | -34.43 | -19.24 | |
| EBITDA Margin | -211.30% | -3.37% | - | - | - | |
| D&A For EBITDA | 1.37 | 0.08 | 0.07 | 0.03 | 0.21 | |
| EBIT | -179.45 | -3.08 | -67.52 | -34.46 | -19.45 | |
| EBIT Margin | -212.92% | -3.46% | - | - | - | |
| Effective Tax Rate | - | 3.48% | - | - | - | |
| Revenue as Reported | 84.28 | 89.15 | 0.03 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.